OMERS ADMINISTRATION Corp Sells 4,402 Shares of Insulet Co. (NASDAQ:PODD)

OMERS ADMINISTRATION Corp reduced its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 34.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,429 shares of the medical instruments supplier's stock after selling 4,402 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Insulet were worth $2,201,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in PODD. SBI Securities Co. Ltd. acquired a new position in Insulet in the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet in the 4th quarter valued at $42,000. SRS Capital Advisors Inc. grew its holdings in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares in the last quarter. Assetmark Inc. grew its holdings in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock valued at $72,000 after buying an additional 149 shares in the last quarter.

Insulet Price Performance

Shares of PODD stock traded up $2.73 on Friday, hitting $324.75. 836,387 shares of the company's stock were exchanged, compared to its average volume of 706,707. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12 month low of $170.67 and a 12 month high of $325.22. The stock has a market cap of $22.85 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The company has a 50 day moving average of $264.14 and a 200 day moving average of $266.69.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same period in the prior year, the company earned $0.73 EPS. Insulet's revenue for the quarter was up 28.8% on a year-over-year basis. On average, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PODD shares. Oppenheimer upped their price objective on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Citigroup upped their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Canaccord Genuity Group increased their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $306.53.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.